2019 Corporate Social Responsibility Report

Company: FOSUN PHARMA (2196)
Year: 2019
Published: 2020-04-24
Status: Processed
View Report

Extracted ESG KPIs

KPIs are organized by ESG aspects.

The types of emissions and respective emissions data.

Indicator Unit 2016 2017 2017-2018 2018 2019 Report Pages
Ammonia nitrogen ton/year 60.55 486 254 130 90
COD (chemical oxygen demand) ton/year 490 841 847 778 90
COD emission intensity kg/RMB10000 of output value 0.33 0.45 0.34 0.27 90, 108
Emission of COD tons/year 841 847 778 108
Emission of NH3-N tons/year 486 254 130 108
Emission of nitrogen oxides tons/year 239 251 258 108
Emission of particles tons/year 41 44 36 108
Emission of sulphur oxides tons/year 245 279 134 108
Investment in building new VOCs treatment facilities for member companies including Zhaohai Pharma, Wanbang Jinqiao, Guilin Pharma, Dongting Pharma and Shine Star million RMB 86 80

Direct (Scope 1) and energy indirect (Scope 2) greenhouse gas emissions (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).

Indicator Unit 2016 2017 2018 2019 Report Pages
Ammonia nitrogen emission intensity kg/RMB10000 of output value 0.041 0.262 0.102 0.046 90, 108
Carbon emission intensity ton/RMB10000 of output value, tons/RMB10000 of output value 0.54 0.41 0.35 84, 108
Carbon emission intensity of Fosun Pharma Group ton/RMB10000 of output value 0.6 0.54 0.41 0.35 86
Direct greenhouse gas emissions of Fosun Pharma Group ton 288447 338285 397106 381580 86
Indirect greenhouse gas emissions of Fosun Pharma Group ton 457732 484501 389265 376563 86
Total carbon emission ton/year 822786 786371 758143 108
Total carbon emissions of Fosun Pharma Group ton 746179 822786 786371 758143 86

Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).

Indicator Unit 2016 2017 2018 2019 Report Pages
Hazardous waste ton, tons/year 1626.8 2396.9 2683.2 4320.8 92, 108
Hazardous waste - Healthcare services ton 827.9 92
Hazardous waste - Medical devices and diagnosis ton 26.9 92
Hazardous waste - Pharmaceutical manufacturing and R&D ton 3466 92
Hazardous waste - Total ton 4320.8 92
Hazardous waste intensity kg/RMB10000 of output value 1.11 1.29 1.08 1.51 90, 92, 108
Hazardous waste subject to landfill disposal ton 271 92
Hazardous waste treated in other ways ton 158.6 92
Number of member enterprises with national green manufacturing and clean production certification 14 82
Total hazardous waste ton 4320.8 92
Total wastewater tons/year 7315890 7565178 7091033 108
Total wastewater discharge ton/year 6785490 7315890 7565178 7091903 90

Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).

Indicator Unit 2016 2017 2018 2019 Report Pages
Domestic waste - Healthcare services ton 3475.8 92
Domestic waste - Medical devices and diagnosis ton 186.6 92
Domestic waste - Pharmaceutical manufacturing and R&D ton 1971.3 92
Domestic waste - Total ton 5633.6 92
Industrial solid waste (non-hazardous) - Medical devices and diagnosis ton 133.1 92
Industrial solid waste (non-hazardous) - Pharmaceutical manufacturing and R&D ton 63496 92
Industrial solid waste (non-hazardous) - Total ton 63629.2 92
Sewage discharge intensity m³/RMB10000 of output value, ton/RMB10000 of output value 4.64 3.95 3.04 2.48 90, 94
Sewage discharge intensity (target) m³/RMB10000 of output value 3.74 94
Total solid waste ton, tons/year 80848 88967 85796.6 73583.6 92, 108
Total solid waste generated by the Group's domestic enterprises ton 73583.6 92
Total solid waste intensity kg/RMB10000 of output value 55.27 48 34.43 25.74 90, 92, 108

Description of emissions target(s) set and steps taken to achieve them.

Indicator Unit 2019 Report Pages
Carbon emission reduction of energy-saving projects tons 17307 84
Consumption of other packaging materials by Fosun Pharma Group ton 66.4 95
Consumption of paper packaging materials by Fosun Pharma Group ton 8550.1 95
Consumption of plastic packaging materials by Fosun Pharma Group ton 2715.3 95
Corresponding carbon reduction by Aleph 4 85
Corresponding carbon reduction by Aohong Pharma 4 85
Corresponding carbon reduction by Baola Laboratory 1 85
Corresponding carbon reduction by Changning Medical 41 85
Corresponding carbon reduction by Dongting Pharma 210 85
Corresponding carbon reduction by Erye Pharma 53 85
Corresponding carbon reduction by Gland Pharma 175 85
Corresponding carbon reduction by Guilin Pharma 676 85
Corresponding carbon reduction by Hesheng Hospital 6 85
Corresponding carbon reduction by Hongqi Pharma 442 85
Corresponding carbon reduction by Huaiyin Medical 51 85
Corresponding carbon reduction by Huanghe Pharma 39 85
Corresponding carbon reduction by Long March Medical 113 85
Corresponding carbon reduction by Shanghai Transfusion 19 85
Corresponding carbon reduction by Wanbang Biopharma 747 85
Corresponding carbon reduction by Wanbang Folon 759 85
Corresponding carbon reduction by Wanbang Jinmao 113 85
Corresponding carbon reduction by Wanbang Pharma 625 85
Corresponding carbon reduction by Wanbang Taisheng 23 85
Corresponding carbon reduction by Yao Pharma 394 85
Corresponding carbon reduction by Yuntuo Optoelectronic 2 85
Corresponding carbon reduction by Zhouhai Pharma 141 85

Description of how hazardous and non-hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them.

Indicator Unit 2019 Report Pages
Hazardous waste incinerated ton 3827.1 92
Hazardous waste recycled ton 64.1 92
Operation expenditure of environmental facilities - Healthcare services RMB'000 469.6 82
Operation expenditure of environmental facilities - Medical devices and diagnosis RMB'000 74.2 82
Operation expenditure of environmental facilities - Pharmaceutical manufacturing and R&D RMB'000 7327.8 82
Total operation expenditure of environmental facilities RMB'000 7871.7 82

Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).

Indicator Unit 2016 2017 2018 2019 Report Pages
Comprehensive energy intensity GJ/RMB1000000 of output value 2.65 84
Diesel consumption of Fosun Pharma Group (segment total) litre 2385197 86
Diesel consumption of Healthcare services segment litre 88031 86
Diesel consumption of Medical devices and diagnosis segment litre 390176 86
Diesel consumption of Pharmaceutical manufacturing and R&D segment litre 1906989 86
Energy consumption other than electricity GJ/year 4648903 5394870 5304416 108
Fuel oil consumption of Fosun Pharma Group (segment total) ton 4900 86
Fuel oil consumption of Pharmaceutical manufacturing and R&D segment ton 4900 86
Gasoline consumption of Fosun Pharma Group (segment total) litre 427227 86
Gasoline consumption of Healthcare services segment litre 158672 86
Gasoline consumption of Medical devices and diagnosis segment litre 74565 86
Gasoline consumption of Pharmaceutical manufacturing and R&D segment litre 193990 86
Liquefied gas consumption of Fosun Pharma Group (segment total) kg 51987 86
Liquefied gas consumption of Healthcare services segment kg 6065 86
Liquefied gas consumption of Medical devices and diagnosis segment kg 5194 86
Liquefied gas consumption of Pharmaceutical manufacturing and R&D segment kg 40728 86
Natural gas consumption of Fosun Pharma Group (segment total) m³ 17968583 86
Natural gas consumption of Healthcare services segment m³ 782275 86
Natural gas consumption of Medical devices and diagnosis segment m³ 230441 86
Natural gas consumption of Pharmaceutical manufacturing and R&D segment m³ 16955867 86
Other energy consumption of Fosun Pharma Group GJ/year 3860500 4648903 5394870 5304016 86
Raw coal consumption of Fosun Pharma Group (segment total) ton 162637 86
Raw coal consumption of Pharmaceutical manufacturing and R&D segment ton 162637 86
Steam consumption of Fosun Pharma Group (segment total) ton 255008 86
Steam consumption of Pharmaceutical manufacturing and R&D segment ton 255008 86
Total electricity consumption kWh/year 513272112 655108860 631436019 108
Total electricity consumption of Fosun Pharma Group kWh/year 478175186 513272112 655861080 613401619 86
Total electricity consumption of Fosun Pharma Group (segment total) kWh/year 631436019 86
Total electricity consumption of Healthcare services segment kWh/year 35344832 86
Total electricity consumption of Medical devices and diagnosis segment kWh/year 13979589 86
Total electricity consumption of Pharmaceutical manufacturing and R&D segment kWh/year 582111598 86
Total energy consumption GJ/year 6496683 7753262 7576550 108
Total energy consumption intensity of Fosun Pharma Group GJ/RMB10000 of output value 4.43 3.51 3.11 2.65 86
Total energy consumption of Fosun Pharma Group GJ/year 5581931 6496683 7753262 7576550 86
Total energy intensity GJ/RMB10000 of output value 3.51 3.11 2.65 108

Water consumption in total and intensity (e.g. per unit of production volume, per facility).

Indicator Unit 2016 2017 2018 2019 Report Pages
Total water consumption m³/year 9515697 9959415 9527927 108
Total water consumption of Fosun Pharma Group m³/year 8769376 9155697 9959415 9527927 95
Total water saving achieved by the Group m³ 255018 94
Total water saving as percentage of total water saving for the year % 2.7 94
Wastewater discharge intensity tons/RMB10000 of output value 3.95 3.04 2.48 108
Water consumption intensity m³/RMB10000 of output value 5.14 3.99 3.33 108
Water consumption intensity of Fosun Pharma Group m³/RMB10000 of output value 5.99 5.14 3.99 3.33 95

Description of energy use efficiency target(s) set and steps taken to achieve them.

Indicator Unit 2019 Report Pages
Capital expenditure of environmental facilities - Healthcare services RMB'000 74.2 82
Capital expenditure of environmental facilities - Medical devices and diagnosis RMB'000 18.7 82
Capital expenditure of environmental facilities - Pharmaceutical manufacturing and R&D RMB'000 45188 82
Capital expenditure of safety facilities - Healthcare services RMB'000 569.1 82
Capital expenditure of safety facilities - Medical devices and diagnosis RMB'000 30.6 82
Capital expenditure of safety facilities - Pharmaceutical manufacturing and R&D RMB'000 3037.1 82
Electricity saved by Aleph kWh 6000 85
Electricity saved by Aohong Pharma kWh 6000 85
Electricity saved by Baola Laboratory kWh 1000 85
Electricity saved by Changning Medical kWh 85000 85
Electricity saved by Dongting Pharma kWh 400000 85
Electricity saved by Erye Pharma kWh 75000 85
Electricity saved by Gland Pharma kWh 188000 85
Electricity saved by Guilin Pharma kWh 350000 85
Electricity saved by Hesheng Hospital kWh 12000 85
Electricity saved by Hongqi Pharma kWh 294000 85
Electricity saved by Huaiyin Medical kWh 72000 85
Electricity saved by Huanghe Pharma kWh 56000 85
Electricity saved by Long March Medical kWh 161000 85
Electricity saved by Shanghai Transfusion kWh 27000 85
Electricity saved by Wanbang Biopharma kWh 1052000 85
Electricity saved by Wanbang Folon kWh 302000 85
Electricity saved by Wanbang Jinmao kWh 160000 85
Electricity saved by Wanbang Pharma kWh 888000 85
Electricity saved by Wanbang Taisheng kWh 29000 85
Electricity saved by Yao Pharma kWh 749000 85
Electricity saved by Yuntuo Optoelectronic kWh 3000 85
Electricity saved by Zhouhai Pharma kWh 200000 85
Fuel oil saved by Hongqi Pharma tons 8.45 85
Natural gas saved by Guilin Pharma m³ 28200 85
Natural gas saved by Wanbang Folon m³ 28200 85

Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.

Indicator Unit 2019 Report Pages
Consumption of glass packaging materials by Fosun Pharma Group ton 11050.5 95
Consumption of metal packaging materials by Fosun Pharma Group ton 352.7 95
Consumption of rubber packaging materials by Fosun Pharma Group ton 854 95
Consumption of wood packaging materials by Fosun Pharma Group ton 22.4 95
Total consumption of packaging materials by Fosun Pharma Group ton 23611 95

Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.

Indicator Unit 2017 2017-2018 2018 2019 Report Pages
Group investment in environmental protection facilities RMB'000 46116 82
Group investment in environmental protection operation and maintenance RMB'000 7878.717 82
Investment in environmental protection RMB'000 7348 15952 12483 108
Investment in upgrading and renovation of sewage treatment facilities of member enterprises such as Wanbang Foton and Anhong Pharma million RMB 20 80
Total capital expenditure of environmental facilities RMB'000 46181.6 82

Total workforce by gender, employment type (for example, full- or part-time), age group and geographical region.

Indicator Unit 2017 2018 2019 Report Pages
Employment rate of ethnic minority employees % 1.6 2.03 3.57 107
Employment rate of people with disabilities % 0.26 0.23 0.24 107
Labor contract conclusion rate 100% 100% 100% 107
Number of R&D staff (excluding QA and QC employees) 1353 1797 2147 107
Number of employees aged 16–20 person 106 140 51 62
Number of employees aged 20–30 person 8951 9768 9975 62
Number of employees aged 30–40 person 8887 9964 11639 62
Number of employees aged 40–50 person 5940 5886 6441 62
Number of employees aged 50–55 person 1546 1486 1894 62
Number of employees aged 55–60 person 683 711 1037 62
Number of employees aged above 60 person 284 290 333 62
Number of employees aged under 40 person 21665 62
Number of employees in Central China (Hubei, Hunan, Henan, Jiangxi) persons 3543 3853 4081 63
Number of employees in Eastern China (Shandong, Jiangsu, Anhui, Zhejiang, Fujian, Shanghai) persons 10096 11094 12590 63
Number of employees in Hong Kong, Macao and Taiwan persons 14 63
Number of employees in Northeast China (Liaoning, Jilin, Heilongjiang) persons 1500 1493 1638 63
Number of employees in Northern China (Beijing, Tianjin, Hebei, Shanxi, Inner Mongolia) persons 241 280 292 63
Number of employees in Southern China (Guangdong, Guangxi, Hainan) persons 4604 4812 4929 63
Number of employees in Southwest China (Sichuan, Yunnan, Guizhou, Tibet, Chongqing) persons 1951 1869 2584 63
Number of employees overseas persons 4448 4844 5256 63
Number of ethnic minority employees 461 574 1114 107
Number of junior college students in the Group persons 6541 7183 8236 63
Number of masters in the Group persons 2453 2922 3312 63
Number of people joining employee birthday parties people 400 71
Number of undergraduates in the Group persons 8193 9137 10242 63
Total number of employees 28884 28245 31370 107
Total number of employees by education level persons 26397 28245 31370 63
Total number of employees of Fosun Pharma Group person 26397 28245 31370 62
Total number of employees with master and doctor degrees 2735 3250 3662 107
Total number of female employees 12764 13273 14830 107
Total number of female employees of Fosun Pharma Group person 12434 13273 14830 62
Total number of male employees 16084 14972 16540 107
Total number of male employees of Fosun Pharma Group person 13963 14972 16540 62
Total working hours - Healthcare services hours 11809641 74
Total working hours - Medical devices and diagnosis hours 4695650 74
Total working hours - Pharmaceutical manufacturing and R&D hours 41753767 74
Total working hours - Total hours 58295057 74
Union coverage rate 100% 100% 100% 107

Employee turnover rate by gender, age group and geographical region.

Indicator Unit 2017 2018 2019 Report Pages
Ration of female employee returning to work and job positions retained till after the completion of the maternity leave 100% 100% 100% 107

Number and rate of work-related fatalities occurred in each of the past three years including the reporting year.

Indicator Unit 2016 2017 2018 2019 Report Pages
LTI rate - Healthcare services 0.423 74
LTI rate - Medical devices and diagnosis 0.213 74
LTI rate - Pharmaceutical manufacturing and R&D 0.335 74
LTI rate - Total 0.343 74
Loss time injury rate per million man-hour per million man-hour 0.58 0.415 0.226 0.343 74, 108
Major injury rate per million man-hour per million man-hour 0.22 0.03 0.038 74
Minor injury rate per million man-hour per million man-hour 0.36 0.385 0.188 0.343 74
Number of Lost Time Injury (LTI) case - Healthcare services 5 74
Number of Lost Time Injury (LTI) case - Medical devices and diagnosis 1 74
Number of Lost Time Injury (LTI) case - Pharmaceutical manufacturing and R&D 14 74
Number of Lost Time Injury (LTI) case - Total 20 74
Number of Recordable Incident (RI) - Healthcare services 5 74
Number of Recordable Incident (RI) - Medical devices and diagnosis 1 74
Number of Recordable Incident (RI) - Pharmaceutical manufacturing and R&D 17 74
Number of Recordable Incident (RI) - Total 23 74
Number of minor injury case - Healthcare services 0.423 74
Number of minor injury case - Medical devices and diagnosis 0.213 74
Number of minor injury case - Pharmaceutical manufacturing and R&D 0.335 74
Number of minor injury case - Total 0.343 74
Occupational hazard exposure rate 12.42% 12.34% 12.66% 108
RI rate - Healthcare services 0.423 74
RI rate - Medical devices and diagnosis 0.213 74
RI rate - Pharmaceutical manufacturing and R&D 0.407 74
RI rate - Total 0.395 74
Recordable incident rate 0.395 72
Recordable incident rate per million man-hour per million man-hour 1.05 0.915 0.433 0.395 74
Recordable injury rate per million man-hour 0.915 0.433 0.395 108

Lost days due to work injury.

Indicator Unit 2019 Report Pages
Lost Time Injury rate 0.343 72
Lost time - Healthcare services 61 74
Lost time - Medical devices and diagnosis 38 74
Lost time - Pharmaceutical manufacturing and R&D 249 74
Lost time - Total 348 74

Description of occupational health and safety measures adopted, and how they are implemented and monitored.

Indicator Unit 2017 2018 2019 Report Pages
Accumulated EHS training hours per person hours 404227 66
Group investment in occupational health and safety RMB'000 8088.013 82
Increase in accumulated EHS training hours per person compared to 2018 70.2% 66
Increase in safety investment over 2018 RMB'000 1587 82
Investment in health and safety RMB'000 3919 3843 5801 108
Number of employees visited by the Company for giving birth to child, illness, and funeral employees 41 71
Number of member enterprises with ISO14001 and/or OHSAS18001 certification 16 82
Number of member enterprises with national safety production standardization certification 24 82
Operation expenditure of safety facilities - Healthcare services RMB'000 437.4 82
Operation expenditure of safety facilities - Medical devices and diagnosis RMB'000 80.8 82
Operation expenditure of safety facilities - Pharmaceutical manufacturing and R&D RMB'000 1646.3 82
Total EHS training hours hours 185067 237572 404227 108
Total EHS training hours (Healthcare services) hours 111339 66
Total EHS training hours (Medical devices and diagnosis) hours 23640 66
Total EHS training hours (Pharmaceutical manufacturing and R&D) hours 277248 66
Total EHS training hours (Total) hours 404227 66
Total capital expenditure of safety facilities RMB'000 3636.8 82
Total operation expenditure of safety facilities RMB'000 2164.5 82

The percentage of employees trained by gender and employee category (e.g. senior management, middle management).

Indicator Unit 2017 2018 2019 Report Pages
Number of birthday parties with different themes organized for employees parties 12 71
Number of doctors in the Group persons 256 328 350 63
R&D expenditure on pharmaceutical manufacturing segment million RMB 1741.2031 34
R&D expense RMB'000 71400.75 102600.54 204140.06 34
R&D investment (including capitalized investment expense) RMB'000 152900.29 250683.56 346322.78 34
R&D investment (including capitalized investment expenses) RMB100 million 15.29 25.07 34.63 107
Total number of EHS training person-times (Healthcare services) person-times 4916 66
Total number of EHS training person-times (Medical devices and diagnosis) person-times 3970 66
Total number of EHS training person-times (Pharmaceutical manufacturing and R&D) person-times 51641 66
Total number of EHS training person-times (Total) person-times 67557 66
Training for Senior Management (Number of trainees) Person 374 376 1193 65
Training for Senior Management (Total training time) Hour 7831 15412 33356 65
Training for employees other than senior management (Number of trainees) Person 22275 25144 30012 65
Training for employees other than senior management (Total training time) Hour 963408 839581 960008 65

The average training hours completed per employee by gender and employee category.

Indicator Unit 2017 2018 2019 Report Pages
Average EHS training hours per person hours 14.65 66
Average EHS training hours per person (Healthcare services) hours 18.03 66
Average EHS training hours per person (Medical devices and diagnosis) hours 12.63 66
Average EHS training hours per person (Pharmaceutical manufacturing and R&D) hours 13.96 66
Average EHS training hours per person (Total) hours 14.65 66
Average EHS training times per person (Healthcare services) times 0.88 66
Average EHS training times per person (Medical devices and diagnosis) times 1.89 66
Average EHS training times per person (Pharmaceutical manufacturing and R&D) times 2.05 66
Average EHS training times per person (Total) times 2.05 66
Average Training Hours Per Person (All employees) hours/person 43 34 31 65
Average Training Hours Per Person (female employees) hours/person 40 37 28 65
Average Training Hours Per Person (male employees) hours/person 47 32 34 65
Average training time per capita, Aohong Pharma 27.7 57
Average training time per capita, Erye Pharma 32 57
Average training time per capita, Guilin Pharma 26 57
Average training time per capita, Hongqi Pharma 67.6 57
Average training time per capita, Wanbang Pharma 48.4 57
Average training time per capita, Yao Pharma 50.1 57
EHS training hours per employee hours 7.86 9.42 14.65 108
EHS training times per employee time 1.8 2.5 2.5 108
Increase in average EHS training hours per person compared to 2018 55.5% 66
Total Training Expenses RMB'000 686 993 1480 65
Total training hours man-hour 971239 854993 993364 107

Number of suppliers by geographical region.

Indicator Unit 2019 Report Pages
Number of suppliers involved in business for the year, Aohong Pharma 60 57
Number of suppliers involved in business for the year, Erye Pharma 182 57
Number of suppliers involved in business for the year, Guilin Pharma 255 57
Number of suppliers involved in business for the year, Hongqi Pharma 104 57
Number of suppliers involved in business for the year, Wanbang Pharma 570 57
Number of suppliers involved in business for the year, Yao Pharma 471 57
Number of suppliers rejected by subsidiaries of the Group 24 57
Number of suppliers under annual review, Aohong Pharma 60 57
Number of suppliers under annual review, Erye Pharma 111 57
Number of suppliers under annual review, Guilin Pharma 255 57
Number of suppliers under annual review, Hongqi Pharma 104 57
Number of suppliers under annual review, Wanbang Pharma 497 57
Number of suppliers under annual review, Yao Pharma 433 57

Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored.

Indicator Unit 2019 Report Pages
Number of group suppliers subject to supply chain audits (end of 2019) 388 28
Number of suppliers under annual review / Number of suppliers involved in business for the year, Aohong Pharma 100.0% 57
Number of suppliers under annual review / Number of suppliers involved in business for the year, Erye Pharma 61.5% 57
Number of suppliers under annual review / Number of suppliers involved in business for the year, Guilin Pharma 100.0% 57
Number of suppliers under annual review / Number of suppliers involved in business for the year, Hongqi Pharma 100.0% 57
Number of suppliers under annual review / Number of suppliers involved in business for the year, Wanbang Pharma 87.2% 57
Number of suppliers under annual review / Number of suppliers involved in business for the year, Yao Pharma 91.9% 57

Number of products and service related complaints received and how they are dealt with.

Indicator Unit 2017 2018 2019 Report Pages
Revenue from healthcare services segment RMB'0000 208847.03 256296.75 303992.27 14
Revenue from medical devices and medical diagnosis segment RMB'0000 321405.08 363886.91 373581.15 14
Revenue from pharmaceutical manufacturing and R&D business segment RMB'0000 1319547.17 1868134.51 2176587.34 14

Description of practices relating to observing and protecting intellectual property rights.

Indicator Unit 2017 2018 2019 Report Pages
Number of applications for innovation projects in the 4th Innovation and Entrepreneurship Competition applications 77 71
Number of patent application 103 84 136 107
Number of patent granted 30 25 47 107

Description of quality assurance process and recall procedures.

Indicator Unit 2019 Report Pages
Number of innovative drugs, generic drugs, biosimilars and consistency evaluation projects 264 34

Description of consumer data protection and privacy policies, and how they are implemented and monitored.

Indicator Unit 2019 Report Pages
Number of media coverage (2019) 7900 28

Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.

Indicator Unit 2017 2018 2019 Report Pages
Under investigation items items 171 215 264 107

Focus areas of contribution (e.g. education, environmental concerns, labour needs, health, culture, sport).

Indicator Unit 2017 2018 2019 Report Pages
Number of employee clubs established by the head office clubs 10 71
Number of enterprises participating in the 4th Innovation and Entrepreneurship Competition enterprises 21 71
Number of secondary school students and below in the Group persons 8954 8675 9230 63
Tax payment RMB'0000 205330 269005 253276.76 14

Resources contributed (e.g. money or time) to the focus area.

Indicator Unit 2017 2018 2019 Report Pages
Number of books in Xinglong Book Store's online and offline libraries books 580 71
Number of families of employees receiving medical resources for more than 60 person times person times 60 71
Number of people visiting Xinglong Book Store's online and offline libraries people 400 71
Revenue RMB'0000 1853355.54 2491827.36 2885515.2 14
Social Contribution per Share 3.84 3.97 4.59 107

The types of emissions and respective emissions data.

Standard Indicator Unit 2017 2018 2019
Airborne Particulate Matter (PM) Emissions tons/year 41 44 36
NOâ‚“ Emissions tons/year 239 251 258
SOâ‚“ Emissions tons/year 245 279 134

Direct (Scope 1) and energy indirect (Scope 2) greenhouse gas emissions (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).

Standard Indicator Unit 2016 2017 2018 2019
Direct GHG Emissions (Scope 1) ton 288447 338285 397106 381580
Indirect Energy Emissions (Scope 2) ton 457732 484501 389265 376563
Total GHG Emissions ton 746179 822786 786371 758143
Total GHG Emissions Intensity (By Revenue) ton/RMB10000 of output value 0.6 0.54 0.41 0.35

Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).

Standard Indicator Unit 2016 2017 2018 2019
Hazardous Waste (Other Recovery) ton 158.6
Hazardous Waste Landfilling ton 271
Total Hazardous Waste ton 1626.8 2396.9 2683.2 4320.8
Total Hazardous Waste Intensity (By Revenue) kg/RMB10000 of output value 1.11 1.29 1.08 1.51

Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).

Standard Indicator Unit 2016 2017 2018 2019
Non-Hazardous Waste (Domestic Waste) ton 5633.6
Non-Hazardous Waste Disposed ton 63629.2
Total Non-Hazardous Waste Intensity (By Revenue) kg/RMB10000 of output value 55.27 48.01 34.43 25.74

Description of emissions target(s) set and steps taken to achieve them.

Standard Indicator Unit 2019
CO2 Emissions Reduction Compared to Last Year tons 17307
GHG Emissions Reduction Compared to Last Year tons 17307

Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).

Standard Indicator Unit 2016 2017 2018 2019
Diesel Fuel Consumption litre 2385197
Energy Consumption Intensity (By Revenue) GJ/RMB10000 of output value 4.43 3.51 3.11 2.65
Fossil Fuel Consumption GJ/year 5304016
Gasoline Consumption litre 427227
LPG Consumption kg 51987
Natural Gas Consumption m³ 17968583
Purchased Electricity kWh/year 478175186 513272112 655861080 613401619
Total Direct Energy Consumption GJ/year 3860500 4648903 5394870 5304016
Total Energy Consumption GJ/year 5581931 6496683 7753262 7576550
Total Indirect Energy Consumption GJ/year 1721431 1847780 2358392 2272534

Water consumption in total and intensity (e.g. per unit of production volume, per facility).

Standard Indicator Unit 2016 2017 2018 2019
Wastewater Discharge Intensity tons/RMB10000 of output value 3.95 3.04 2.48
Water Consumption m³/year 8769376 9515697 9959415 9527927
Water Consumption Intensity (By Revenue) m³/RMB10000 of output value 5.99 5.14 3.99 3.33

Description of energy use efficiency target(s) set and steps taken to achieve them.

Standard Indicator Unit 2019
Electricity Usage Reduction Compared to Last Year kWh 5_011_000
Investment in Energy-saving and Emission-reduction Technology Transformation RMB'000 45_280.9

Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.

Standard Indicator Unit 2019
Packaging Material Consumption (Glass) ton 11050.5
Packaging Material Consumption (Metal) ton 352.7
Packaging Material Consumption (Rubber) ton 854
Packaging Materials Consumed ton 23611
Usage of Packaging Materials (Wood) ton 22.4

Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.

Standard Indicator Unit 2017 2018 2019
Total Investment in Ecological Restoration RMB'000 7348 15952 12483

Total workforce by gender, employment type (for example, full- or part-time), age group and geographical region.

Standard Indicator Unit 2017 2018 2019
Number of Employees Aged 30-50 person 14827 15850 18080
Number of Employees Aged Above 50 person 2514 3487 4257
Number of Employees Aged Below 30 person 9057 9908 10026
Number of Employees in Central China persons 3543 3853 4081
Number of Employees in East China persons 10096 11094 12590
Number of Employees in Hong Kong persons 14
Number of Employees in North China persons 241 280 292
Number of Employees in Northeast China persons 1500 1493 1638
Number of Employees in Overseas persons 4448 4844 5256
Number of Employees in South China persons 4604 4812 4929
Number of Employees in Southwest China persons 1951 1869 2584
Number of Female Employees 12764 13273 14830
Number of Male Employees 16084 14972 16540
Number of Total Employees 28884 28245 31370

Employee turnover rate by gender, age group and geographical region.

Standard Indicator Unit 2017 2018 2019
Percentage of Employees still Employed 12 Months after Return to Work (Female) % 100 100 100

Lost days due to work injury.

Standard Indicator Unit 2019
Lost Days Due to Work-related Injuries days 348
Lost Time Injury Frequency Rate (LTIFR/LTIR) 0.343

Description of occupational health and safety measures adopted, and how they are implemented and monitored.

Standard Indicator Unit 2017 2018 2019
Investment in Work Safety RMB'000 3919 3843 5801
Total Hours of Safety Training for Employees hours 185067 237572 404227

The percentage of employees trained by gender and employee category (e.g. senior management, middle management).

Standard Indicator Unit 2017 2018 2019
Percentage of Trained General Employees % 100 100 100
Percentage of Trained Senior Management % 100 100 100

The average training hours completed per employee by gender and employee category.

Standard Indicator Unit 2017 2018 2019
Average Training Hours (Female) hours/person 40 37 28
Average Training Hours (Male) hours/person 47 32 34
Average Training Hours per Employee hours/person 43 34 31
Total Training Hours man-hour 971239 854993 993364

Number of suppliers by geographical region.

Standard Indicator Unit 2019
Number of Suppliers in Hong Kong 9
Number of Suppliers in Mainland China 1365
Number of Suppliers in Overseas 268
Number of Total Suppliers 1642

Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored.

Standard Indicator Unit 2019
Percentage of Critical Suppliers Covered by CSR Audit % 100

Description of practices relating to observing and protecting intellectual property rights.

Standard Indicator Unit 2017 2018 2019
Number of Patents Applied 103 84 136
Number of Patents Granted 30 25 47

Resources contributed (e.g. money or time) to the focus area.

Standard Indicator Unit 2019
Number of Participations in Volunteer Activities person times 60